In Vivo Myogenic Potential of Human CD133+ Muscle-derived Stem Cells: A Quantitative Study
In Vivo Myogenic Potential of Human CD133+ Muscle-derived Stem Cells: A Quantitative Study
复制标题
DOI：
10.1038/mt.2009.167
复制
发表时间：
2009-10-01
影响因子：
12.4
通讯作者：
Mouly, Vincent
中科院分区：
文献类型：
--
作者：
Negroni, Elisa;Riederer, Ingo;Mouly, Vincent
近年来，许多报道已经在小鼠中鉴定出不同来源的肌源性细胞，其不同于在体内表现出可变的肌源性潜能的卫星细胞。肌源性干细胞也在人类中被描述，尽管它们的再生潜力很少被量化。在这项研究中，我们研究了基于干细胞标志物CD 133的表达的人肌源性细胞的成肌潜力，与已经用于临床试验的真正的卫星细胞相比。在Rag 2（-/-）gamma C-/- C5（-/-）小鼠中评价了肌内注射时这些细胞参与肌肉再生和促进卫星细胞库更新的效率，其中肌肉变性由冷冻损伤诱导。我们证明，与人成肌细胞相比，人肌肉来源的CD 133（+）细胞显示出更大的再生能力。与注射人成肌细胞后观察到的相比，表达人蛋白质的纤维的数量和卫星细胞位置中的人细胞的数量都显著增加。此外，与人成肌细胞相比，CD 133（+）/CD 34（+）细胞在宿主肌肉中表现出更好的分散性。我们认为，肌肉来源的CD 133（+）细胞可能是一个有吸引力的候选细胞治疗。
In recent years, numerous reports have identified in mouse different sources of myogenic cells distinct from satellite cells that exhibited a variable myogenic potential in vivo. Myogenic stem cells have also been described in humans, although their regenerative potential has rarely been quantified. In this study, we have investigated the myogenic potential of human muscle-derived cells based on the expression of the stem cell marker CD133 as compared to bona fide satellite cells already used in clinical trials. The efficiency of these cells to participate in muscle regeneration and contribute to the renewal of the satellite cell pool, when injected intramuscularly, has been evaluated in the Rag2(-/-) gamma C-/- C5(-/-) mouse in which muscle degeneration is induced by cryoinjury. We demonstrate that human muscle-derived CD133(+) cells showed a much greater regenerative capacity when compared to human myoblasts. The number of fibers expressing human proteins and the number of human cells in a satellite cell position are all dramatically increased when compared to those observed after injection of human myoblasts. In addition, CD133(+)/CD34(+) cells exhibited a better dispersion in the host muscle when compared to human myoblasts. We propose that muscle-derived CD133(+) cells could be an attractive candidate for cellular therapy.